FDA Stresses Importance Of Fair Balance; Warning Letters Continue To Climb In 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug makers should “be wary” when making promotional claims, McDermott Will & Emery’s Friede cautions.